Human Molecular Genetics Advance Access originally published online on July 24, 2008
Human Molecular Genetics 2008 17(20):3223-3235; doi:10.1093/hmg/ddn218
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism
1 Laboratory for Structural Neuropathology 2 Laboratory for Neuronal Circuit Dynamics 3 Biomolecular Characterization, Discovery Research Institute, Molecular Neuropathology Group, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama 351-0198, Japan
* To whom correspondence should be addressed. Tel: +81 484679702; Fax: +81 484624796; Email: nukina{at}brain.riken.jp
Received April 22, 2008; Revised June 26, 2008; Accepted July 23, 2008
Huntington's disease (HD) is a fatal neurodegenerative disorder. Despite a tremendous effort to develop therapeutic tools in several HD models, there is no effective cure at present. Acidosis has been observed previously in cellular and in in vivo models as well as in the brains of HD patients. Here we challenged HD models with amiloride (Ami) derivative benzamil (Ben), a chemical agent used to rescue acid-sensing ion channel (ASIC)-dependent acidotoxicity, to examine whether chronic acidosis is an important part of the HD pathomechanism and whether these drugs could be used as novel therapeutic agents. Ben markedly reduced the huntingtin-polyglutamine (htt-polyQ) aggregation in an inducible cellular system, and the therapeutic value of Ben was successfully recapitulated in the R6/2 animal model of HD. To reveal the mechanism of action, Ben was found to be able to alleviate the inhibition of the ubiquitin-proteasome system (UPS) activity, resulting in enhanced degradation of soluble htt-polyQ specifically in its pathological range. More importantly, we were able to demonstrate that blocking the expression of a specific isoform of ASIC (asic1a), one of the many molecular targets of Ben, led to an enhancement of UPS activity and this blockade also decreased htt-polyQ aggregation in the striatum of R6/2 mice. In conclusion, we believe that chemical compounds that target ASIC1a or pharmacological alleviation of UPS inhibition would be an effective and promising approach to combat HD and other polyQ-related disorders.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. O. Bauer, H. K. Wong, F. Oyama, A. Goswami, M. Okuno, Y. Kino, H. Miyazaki, and N. Nukina Inhibition of Rho Kinases Enhances the Degradation of Mutant Huntingtin J. Biol. Chem., May 8, 2009; 284(19): 13153 - 13164. [Abstract] [Full Text] [PDF]
|
|